Molecular Analysis for Therapy Choice (MATCH)
Clinical Trial Information
Trial Contact: Frankos, Marie; Durand, Jennifer; Roberts, Michael Todd; Walton, Sherri; De Leon, Ma Theresa
To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival